Literature DB >> 19614673

Structurally diverse peroxisome proliferator-activated receptor agonists induce apoptosis in human uro-epithelial cells by a receptor-independent mechanism involving store-operated calcium channels.

B Chopra1, N T Georgopoulos, A Nicholl, J Hinley, M B Oleksiewicz, J Southgate.   

Abstract

OBJECTIVES: Peroxisome proliferator-activated receptors (PPARs) are implicated in epithelial cell proliferation and differentiation, but investigation has been confounded by potential off-target effects of some synthetic PPAR ligands. Our aim was to determine mechanisms underlying the pro-apoptotic effect of synthetic PPAR agonists in normal human bladder uro-epithelial (urothelial) cells and to reconcile this with the role of PPARs in urothelial cytodifferentiation.
MATERIALS AND METHODS: Normal human urothelial (NHU) cells were grown as non-immortal lines in vitro and exposed to structurally diverse agonists ciglitazone, troglitazone, rosiglitazone (PPARgamma), ragaglitazar (PPARalpha/gamma), fenofibrate (PPARalpha) and L165041 (PPARbeta/delta).
RESULTS: NHU cells underwent apoptosis following acute exposure to ciglitazone, troglitazone or ragaglitazar, but not fenofibrate, L165041 or rosiglitazone, and this was independent of ERK or p38 MAP-kinase activation. Pro-apoptotic agonists induced sustained increases in intracellular calcium, whereas removal of extracellular calcium altered the kinetics of ciglitazone-mediated calcium release from sustained to transient. Cell death was accompanied by plasma-membrane disruption, loss of mitochondrial membrane-potential and caspase-9/caspase-3 activation. PPARgamma-mediated apoptosis was unaffected following pre-treatment with PPARgamma antagonist T0070907 and was strongly attenuated by store-operated calcium channel (SOC) inhibitors 2-APB and SKF-96365.
CONCLUSIONS: Our results provide a mechanistic basis for the ability of some PPAR agonists to induce death in NHU cells and demonstrate that apoptosis is mediated via PPAR-independent mechanisms, involving intracellular calcium changes, activation of SOCs and induction of the mitochondrial apoptotic pathway.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19614673      PMCID: PMC6495987          DOI: 10.1111/j.1365-2184.2009.00628.x

Source DB:  PubMed          Journal:  Cell Prolif        ISSN: 0960-7722            Impact factor:   6.831


  41 in total

1.  PPARgamma signaling: one size fits all?

Authors:  Anjali Jain; David B Agus
Journal:  Cell Cycle       Date:  2004-11-08       Impact factor: 4.534

2.  PPARgamma-regulated tight junction development during human urothelial cytodifferentiation.

Authors:  Claire L Varley; Mary A E Garthwaite; William Cross; Jennifer Hinley; Ludwik K Trejdosiewicz; Jennifer Southgate
Journal:  J Cell Physiol       Date:  2006-08       Impact factor: 6.384

3.  Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma.

Authors:  G D Demetri; C D Fletcher; E Mueller; P Sarraf; R Naujoks; N Campbell; B M Spiegelman; S Singer
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

4.  A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis.

Authors:  N Suh; Y Wang; C R Williams; R Risingsong; T Gilmer; T M Willson; M B Sporn
Journal:  Cancer Res       Date:  1999-11-15       Impact factor: 12.701

5.  Death receptor-induced apoptotic and necrotic cell death: differential role of caspases and mitochondria.

Authors:  G Denecker; D Vercammen; M Steemans; T Vanden Berghe; G Brouckaert; G Van Loo; B Zhivotovsky; W Fiers; J Grooten; W Declercq; P Vandenabeele
Journal:  Cell Death Differ       Date:  2001-08       Impact factor: 15.828

6.  Role of peroxisome proliferator-activated receptor gamma and its ligands in non-neoplastic and neoplastic human urothelial cells.

Authors:  K I Nakashiro; Y Hayashi; A Kita; T Tamatani; A Chlenski; N Usuda; K Hattori; J K Reddy; R Oyasu
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

7.  Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans.

Authors:  Y Guan; Y Zhang; L Davis; M D Breyer
Journal:  Am J Physiol       Date:  1997-12

8.  FOXA1 and IRF-1 intermediary transcriptional regulators of PPARgamma-induced urothelial cytodifferentiation.

Authors:  C L Varley; E J Bacon; J C Holder; J Southgate
Journal:  Cell Death Differ       Date:  2008-08-08       Impact factor: 15.828

9.  Trans-species comparison of PPAR and RXR expression by rat and human urothelial tissues.

Authors:  Bikramjit Chopra; Jennifer Hinley; Martin B Oleksiewicz; Jennifer Southgate
Journal:  Toxicol Pathol       Date:  2008-04-25       Impact factor: 1.902

Review 10.  Nongenomic actions of steroid hormones.

Authors:  Ralf Lösel; Martin Wehling
Journal:  Nat Rev Mol Cell Biol       Date:  2003-01       Impact factor: 94.444

View more
  4 in total

Review 1.  Scientific Evidence and Controversies About Pioglitazone and Bladder Cancer: Which Lessons Can Be Drawn?

Authors:  Jean-Luc Faillie; Pierre Petit; Jean-Louis Montastruc; Dominique Hillaire-Buys
Journal:  Drug Saf       Date:  2013-09       Impact factor: 5.606

2.  Differential regulation of growth-promoting signalling pathways by E-cadherin.

Authors:  Nikolaos T Georgopoulos; Lisa A Kirkwood; Dawn C Walker; Jennifer Southgate
Journal:  PLoS One       Date:  2010-10-26       Impact factor: 3.240

3.  Effect of pioglitazone on the fructose-induced abdominal adipose tissue dysfunction.

Authors:  Ana Alzamendi; Andrés Giovambattista; María E García; Oscar R Rebolledo; Juan J Gagliardino; Eduardo Spinedi
Journal:  PPAR Res       Date:  2012-10-02       Impact factor: 4.964

4.  Ketamine-Induced Apoptosis in Normal Human Urothelial Cells: A Direct, N-Methyl-d-Aspartate Receptor-Independent Pathway Characterized by Mitochondrial Stress.

Authors:  Simon C Baker; Saqib Shabir; Nikolaos T Georgopoulos; Jennifer Southgate
Journal:  Am J Pathol       Date:  2016-03-18       Impact factor: 4.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.